Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Month: December 2025
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Nova Leap Health Corp. Launches Care Management Division In the United States
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025...
Nova Leap Health Corp. Launches Care Management Division In the United States
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025...
Nova Leap Health Corp. Launches Care Management Division In the United States
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
Starton Therapeutics to Present at Biotech Showcase 2026
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in...
Starton Therapeutics to Present at Biotech Showcase 2026
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in...
Starton Therapeutics to Present at Biotech Showcase 2026
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in...
Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in...
Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in...
Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in...
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic...
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic...
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic...